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In this special issue of  Burns & Trauma, we focus on 
transplant immunology, highlighting the pressing issues 
in the field and emerging strategies in resolving these 
issues, especially in the area of  tolerance induction. 
The ultimate goal is to achieve transplant tolerance, 
a state of  stable transplant survival without lifelong 
immunosuppression.
This topic is a timely one, as solid organ transplantation 
has clearly come of  age, and within a relatively short 
period of  time, transplantation developed from just an 
exploratory procedure to a preferred treatment of  choice 
for end-stage organ failure. From a clinical perspective, 
the short-term transplant survival has been excellent now, 
with 1-year survival greater than 90% for most organ 
transplants in the clinic. This is mainly due to improvements 
in immunosuppressive protocols that most effectively 
control acute rejection. This remarkable accomplishment 
has resulted in significant advances in many other fronts 
in clinical medicine, including vascularized composite 
tissue allotransplantation (VCA) for trauma patients whose 
injuries are just beyond repair by conventional surgeries. 
The current experience with hand and face transplantation 
in the world for those with debilitating and dysfiguring 
injuries has generated tremendous enthusiasm in that 
transplantation of  multiple different tissues and organs 
together as a single unit (like a hand) can offer a therapeutic 
option for some patients that otherwise have no choice of  
treatment at all.
However, VCA for burn and trauma patients creates both 
challenges and opportunities. Composite tissue grafts 
(e.g., limbs and face transplants), like most transplanted 
organs, are subject to immune attacks by the recipients. 
However, unlike other solid organ transplantation, 
composite tissue transplants are composed of  multiple 
tissues with different functional properties, including 
skin, muscle, bone, and nerves. These tissues also have 
different immunological features. Therefore, it is important 
to elucidate the key features unique to individual tissues 
and how such different tissues interface with the recipient’s 
immune system. To date, patients with a composite tissue 
transplant have to take immunosuppression drugs for 
life, the risk and the benefit of  VCA versus side effects 
of  long-term immunosuppression need to be carefully 
considered. Key areas of  future investigation should 
include fundamental mechanisms of  composite tissue 
rejection, new protocols aimed at producing transplant 
survival without lifelong immunosuppression drugs, 
and innovative ways to minimize tissue injury and 
foster tissue regeneration. Studies in areas may bring 
new advances to transplant medicine that will benefit 
patients who suffer from disfiguring trauma and burns. 
For this topic, Tullius et al., (next issue) will summarize 
the current status of  VCA, highlighting new development 
and challenges in the field. Kloc et al., discussed the 
mechanisms of  chronic allograft rejection, the cell types 
involved, and new emerging therapies to treat or prevent 
chronic graft loss. [1] One of  the key features of  chronic 
rejection is the slow and progressive destruction of  graft 
vasculature, which is a major cause of  graft loss in clinical 
transplantation, and because of  this, there is an urgent 
need now to develop new therapies to prevent damage 
of  graft vasculature. Chen et al., focused on the role of  
cytokines in the allograft response, pointing to the facts 
that cytokines can be proinflammatory favoring transplant 
rejection or anti-inflammatory facilitating tolerance. Thus, 
cytokines may be a powerful tool with which to selectively 
and specifically modulate the immune responses.[2] Dai 
et al., highlighted the importance of  regulatory cells in the 
induction of  transplant tolerance, the diversity of  immune 
cells with regulatory properties, and emerging approaches 
to therapeutically target regulatory cells in the clinic.[3] 
Moreover, Zhou et al., described an interleukin (IL)-10 
related T cell proliferation inhibition in mixed lymphocyte 
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reaction induced by multiple alloantigens, providing 
new evidence for the mechanism of  T cell intraclonal 
competition.[4] Hopefully, these articles will provide 
the readers with a focused glimpse of  several rapidly 
developing areas of  VCA as well as challenges that are 
associated with it, especially in the area of  reprogramming 
the immune system to create lasting tolerance.
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